A
Allele Biotech
Private, san diego-based company
About Allele Biotech
Allele Biotechnology and Pharmaceuticals, Inc. operates as a Contract Development and Manufacturing Organization (CDMO) and a key supplier of molecular biology reagents, positioning itself at the intersection of research tools and therapeutic development. Founded in 1999 by Dr. Jiwu Wang, a biochemist with a Ph.D. from the University of Southern California and extensive experience in molecular biology, the company leverages its scientific roots to serve biomedical researchers and pharmaceutical partners. Dr. Wang's research background in pre-mRNA splicing and his numerous patents in RNA interference, imaging, and stem cell production have fundamentally shaped the company's trajectory.
The company's business model is multifaceted, generating revenue through the sale of proprietary research products, technology licensing, and offering comprehensive CDMO services. Its client base ranges from academic researchers to large pharmaceutical companies like Astellas. A cornerstone of Allele's offerings is its induced Pluripotent Stem Cell (iPSC) technology. The company has developed patented, feeder-free methods using messenger RNA (mRNA) to create clinical-grade iPSC lines, which are crucial for developing cell therapies for conditions such as diabetes and spinal injuries. Allele established a cGMP-compliant facility in San Diego to produce and bank these iPSC lines, offering both off-the-shelf and custom cell line development.
Another significant area of operation is the development of single-domain nanoantibodies (nAbs) derived from camelids. These small, highly stable antibodies offer advantages in specificity and tissue permeability, making them suitable for diagnostics and as biologics in immunology and oncology. Allele's involvement in this field dates back to 2008. Furthermore, the company is known for its high-performance fluorescent proteins, most notably mNeonGreen, which is considered one of the brightest monomeric fluorescent proteins available and is used extensively in biomedical imaging and research. The intellectual property surrounding mNeonGreen led to patent infringement lawsuits against major pharmaceutical companies for its unauthorized use in COVID-19 research. During the COVID-19 pandemic, Allele utilized its iPSC and nanoantibody platforms to develop diagnostics and therapeutic candidates.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 26
- Open positions
- None listed
- Dealroom signal
- 72.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, DNA, Genetics and genomics, Packaging and Containers, Spinout, Genome Engineering, Biotech and Pharma, DT and LS, science-based
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANT✓Other financing | Oct 2018 | — | — | National Institute of General Medical Sciences | — |
| SERIES B✓Equity / VC | Oct 2016 | $11M | $44M | Undisclosed | — |
Growth signals
Latest recorded traffic for Allele Biotech is 1.9K monthly website visits, down 47.2% over the last three months. Allele Biotech's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Allele Biotech in the San Diego ecosystem
The Allele Biotech office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
National Institute of General Medical Sciences
Series A2 investors entered at this stage
- YCYuan Capital
Eric Xu
Other known investors1 additional known investor
University of California, San Diego
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Allele Biotech on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Allele Biotech’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








